| Mr Krisna P Chai, MD | |
|
710 Lawrence Expy, Santa Clara, CA 95051-5173 | |
| (408) 851-1000 | |
| Not Available |
| Full Name | Mr Krisna P Chai |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 22 Years |
| Location | 710 Lawrence Expy, Santa Clara, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013007202 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | A85306 (California) | Primary |
| 207RG0100X | Internal Medicine - Gastroenterology | 48833-020 (Wisconsin) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kaiser Foundation Hospital-santa Clara | Santa clara, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Permanente Medical Group Inc | 8921910225 | 7800 |
News Archive
Tarsa Therapeutics today reported that it presented positive safety and efficacy data from its Phase III ORACAL trial of OSTORA, the company's oral recombinant salmon calcitonin tablet in development for the treatment of postmenopausal osteoporosis.
JuvoLab, a company focused on value creation in the life sciences industry, today announced the release of a unique study detailing the entire global oncology community's utilization of Twitter to enhance scientific discussion at the ASCO 2010 Annual Meeting. This pioneering study analyzed over 4450 tweets, generated by more than 680 users over the course of the conference, and provides clarity and insight into the use of Twitter from breaking clinical news and engaging in clinical discussion to compliant corporate promotion by industry leaders.
Lifestyle interventions, including physical activity and structured weight loss programs, can result in significant weight loss for overweight, obese and severely obese adults, according to two reports that were posted online today by JAMA. The studies and accompanying editorials were made available early online to coincide with the presentation of these papers at the 28th Annual Scientific Meeting of the Obesity Society. The articles will appear in the October 27 print issue of JAMA.
The U.S. Food and Drug Administration has approved the first ablation catheters for the treatment of atrial fibrillation (uncoordinated contractions of the upper heart chambers), one of the most common types of arrhythmias-or abnormal heart rhythms-affecting more than two million Americans.
Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each patient's tumor has also given researchers clearer understanding of which patients should receive the combination.
› Verified 2 days ago
| Entity Name | Permanente Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073606299 PECOS PAC ID: 8921910225 Enrollment ID: O20031104000710 |
News Archive
Tarsa Therapeutics today reported that it presented positive safety and efficacy data from its Phase III ORACAL trial of OSTORA, the company's oral recombinant salmon calcitonin tablet in development for the treatment of postmenopausal osteoporosis.
JuvoLab, a company focused on value creation in the life sciences industry, today announced the release of a unique study detailing the entire global oncology community's utilization of Twitter to enhance scientific discussion at the ASCO 2010 Annual Meeting. This pioneering study analyzed over 4450 tweets, generated by more than 680 users over the course of the conference, and provides clarity and insight into the use of Twitter from breaking clinical news and engaging in clinical discussion to compliant corporate promotion by industry leaders.
Lifestyle interventions, including physical activity and structured weight loss programs, can result in significant weight loss for overweight, obese and severely obese adults, according to two reports that were posted online today by JAMA. The studies and accompanying editorials were made available early online to coincide with the presentation of these papers at the 28th Annual Scientific Meeting of the Obesity Society. The articles will appear in the October 27 print issue of JAMA.
The U.S. Food and Drug Administration has approved the first ablation catheters for the treatment of atrial fibrillation (uncoordinated contractions of the upper heart chambers), one of the most common types of arrhythmias-or abnormal heart rhythms-affecting more than two million Americans.
Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each patient's tumor has also given researchers clearer understanding of which patients should receive the combination.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Krisna P Chai, MD 710 Lawrence Expy, Santa Clara, CA 95051-5173 Ph: (408) 851-1000 | Mr Krisna P Chai, MD 710 Lawrence Expy, Santa Clara, CA 95051-5173 Ph: (408) 851-1000 |
News Archive
Tarsa Therapeutics today reported that it presented positive safety and efficacy data from its Phase III ORACAL trial of OSTORA, the company's oral recombinant salmon calcitonin tablet in development for the treatment of postmenopausal osteoporosis.
JuvoLab, a company focused on value creation in the life sciences industry, today announced the release of a unique study detailing the entire global oncology community's utilization of Twitter to enhance scientific discussion at the ASCO 2010 Annual Meeting. This pioneering study analyzed over 4450 tweets, generated by more than 680 users over the course of the conference, and provides clarity and insight into the use of Twitter from breaking clinical news and engaging in clinical discussion to compliant corporate promotion by industry leaders.
Lifestyle interventions, including physical activity and structured weight loss programs, can result in significant weight loss for overweight, obese and severely obese adults, according to two reports that were posted online today by JAMA. The studies and accompanying editorials were made available early online to coincide with the presentation of these papers at the 28th Annual Scientific Meeting of the Obesity Society. The articles will appear in the October 27 print issue of JAMA.
The U.S. Food and Drug Administration has approved the first ablation catheters for the treatment of atrial fibrillation (uncoordinated contractions of the upper heart chambers), one of the most common types of arrhythmias-or abnormal heart rhythms-affecting more than two million Americans.
Treating advanced melanoma patients with either a combination of the immunotherapy drugs nivolumab (Opdivo™) and ipilimumab (Yervoy™) or nivolumab alone significantly increases progression-free survival (PFS) over using ipilimumab alone, according to new findings from researchers at Memorial Sloan Kettering Cancer Center (MSK) simultaneously presented today at the American Society of Clinical Oncology (ASCO) annual meeting and published online in the New England Journal of Medicine (NEJM). Examining specific characteristics of each patient's tumor has also given researchers clearer understanding of which patients should receive the combination.
› Verified 2 days ago
Uma Devi Kantamuneni, M.D Gastroenterology Medicare: Medicare Enrolled Practice Location: 3655 Pruneridge Ave Apt 224, Santa Clara, CA 95051 Phone: 408-564-7469 | |
Hui Wu, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 700 Lawrence Expy, Santa Clara, CA 95051 Phone: 408-605-7333 | |
Alan H. Man, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 710 Lawrence Expy, Santa Clara, CA 95051 Phone: 408-851-1000 | |
Melody Chung, Gastroenterology Medicare: Medicare Enrolled Practice Location: 700 Lawrence Expy, Santa Clara, CA 95051 Phone: 408-851-3830 | |
Inna Strugatsky, Gastroenterology Medicare: Medicare Enrolled Practice Location: 2734 El Camino Real, Santa Clara, CA 95051 Phone: 408-739-6000 | |
Asma Habib, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 2734 El Camino Real, Santa Clara, CA 95051 Phone: 408-241-3801 |